文献速递中医内科中药与中成药合理使用

网络药理学与蛋白质组学整合分析揭示脱敏止嚏汤治疗变应性鼻炎的关键靶点

Integrative analysis of network pharmacology and proteomics to identify key targets of Tuomin-Zhiti-Decoction for allergic rhinitis.
PubMed 文献 · J Ethnopharmacol · 2022-06-06

该研究以卵清蛋白(OVA)诱导的变应性鼻炎(AR)小鼠模型评价脱敏止嚏汤(TZD)的抗AR作用,并结合网络药理学与蛋白质组学分析其潜在靶点与机制。结果显示TZD可降低OVA特异性IgE和组胺释放、改善鼻部症状与鼻黏膜损伤、调节Th1/Th2/Th17平衡;整合分析提示IL-6和CD40可能为关键蛋白靶点,槲皮素与汉黄芩素可能发挥重要作用,分子对接显示核心活性化合物与关键靶点结合紧密。

要点

  • TZD可降低OVA特异性IgE与组胺释放,改善AR小鼠鼻部症状及鼻黏膜损伤。
  • TZD可调节Th1/Th2/Th17平衡,蛋白质组学识别出41个差异表达蛋白。
  • 整合分析提示IL-6、CD40为潜在靶点,槲皮素与汉黄芩素可能作用较强。

核心结论

  • TZD可能具有治疗AR的潜力,整合网络药理学与蛋白质组学揭示了其潜在机制与靶点。

研究设计与样本

  • 研究采用OVA鼻腔激发建立AR小鼠模型,经TZD治疗后检测鼻部症状、组织病理学及Th1/Th2相关细胞因子。
  • 研究整合网络药理学与蛋白质组学分析TZD抗AR的活性化合物、潜在靶点与机制,并用分子对接评价关键靶点与匹配活性化合物的结合亲和力。

主要发现

  • TZD通过降低OVA特异性IgE和组胺释放控制过敏反应。
  • TZD减少小鼠鼻摩擦与喷嚏次数,减轻AR诱导的鼻黏膜损伤,鼻部症状明显改善。
  • TZD调节Th1/Th2/Th17平衡。
  • 蛋白质组学分析识别出41个差异表达蛋白(DEPs)。
  • 整合分析提示IL-6和CD40可能为TZD抗AR的潜在蛋白靶点,槲皮素与汉黄芩素可能在AR中发挥更有效作用;分子对接显示TZD核心活性化合物可与关键靶点紧密结合。

临床怎么用

  • 该研究为TZD治疗AR提供了潜在靶点与机制层面的实验依据,支持其作为AR候选方剂的进一步开发。
  • IL-6、CD40及槲皮素、汉黄芩素可作为后续机制验证与质量标志物研究的候选方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Allergic rhinitis (AR) is one of most prevalent disease and it is urgent need to develop new drug. Tuomin-Zhiti-Decoction (TZD) is a traditional medicinal compound consisting of eleven different herbs and has a significant effect on AR, yet its underlying mechanism is still unknown. AIM OF THE STUDY: The aim of this study was to confirm the anti-AR effects and the underlying mechanism of TZD. Integrative analysis of network pharmacology and proteomics to explore the common mechanism of TZD treating AR. MATERIALS AND METHODS: Mice were subjected to serial intranasal challenge with ovalbumin (OVA), we examinaed the nasal symptoms, histopathology and Th1/Th2-related cytokines after TZD treatments. Active compounds, potential targets and underlying mechanisms of TZD against AR were systematically clarified by integrating network pharmacology and proteomics analysis. Then we validated the binding affinity between the key potential targets and matching active compounds using molecular docking evaluation. RESULTS: TZD controlled allergy by reduction of OVA-specific immunoglobulin E (IgE) and histamine release. In nasal tissue, TZD decreased nasal rubbing, sneezing and reduced AR-induced damage to nasal mucosa, accordingly, the nasal symptoms were also clearly ameliorated. Moreover, TZD modulated the balance of Th1/Th2/Th17. The proteomics analysis recognized 41 differentially expressed proteins (DEPs). Integrative analysis of network pharmacology and proteomics, we found IL-6 and CD40 could be potential protein targets of TZD against AR, quercetin and wogonin may play more effective roles in AR. Active core compounds of TZD could bind closely to the key targets by molecular docking. CONCLUSION: TZD may have therapeutic potential for treating AR, integrating analysis of network pharmacology and proteomics uncovered the underlying mechanism and targets of TZD, which provides a scientific method for the sensible development of traditional Chinese medicine.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Cheng J, Zhang M, Zheng Y, et al. Integrative analysis of network pharmacology and proteomics to identify key targets of Tuomin-Zhiti-Decoction for allergic rhinitis. J Ethnopharmacol. 2022. PMID: 35680038. doi:10.1016/j.jep.2022.115448

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。